Interactive Investor
>>

Leap Therapeutics Inc (NASDAQ:LPTX) Share Price

LPTX

Leap Therapeutics Inc

North American company

Right Arrow 1

Healthcare

Right Arrow 2

Biotechnology

 / 

- / -
-
- / -
-
-
-

NAV Price

-

Last Traded

-

Chg

-

-

XNAS

-

Updated: -

Research

News & analysis

Loading...

Times are shown in GMT-4, values are delayed by at least 15 minutes. Past performance is not a reliable indicator of future results.

This stock can be held in:

 / 

- / -
-
- / -
-
-
-

Company Profile

Leap Therapeutics Inc is a biopharmaceutical company developing novel therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. Its clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1. DKK1 is a protein that regulates the Wnt signaling pathways and enables tumor cells to proliferate and spread, as well as suppresses the immune system from attacking the tumor. The company is studying DKN-01 in multiple ongoing clinical trials in patients with esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, or prostate cancer. Its other clinical studies include P100, P102, P204, P205, and P103.Leap Therapeutics Inc is a biopharmaceutical company . The company is engaged in acquiring and developing novel therapeutics at the leading edge of cancer biology.

NASDAQ:LPTX

US52187K1016

USD

Loading...

Loading Comparison

Latest LPTX News